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K E YWORD S : insulin analogues, insulin therapy, type 2 diabetes
Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D) that, in insulin-treated people can result in decreased insulin clear-
ance and increased risk of hypoglycaemia.1 Severe hypoglycaemia is asso-
ciated with increased morbidity and mortality, particularly in relation to
cardiovascular disease (CVD).2,3 CKD is associated with an increased risk
of hypoglycaemic events in people with or without diabetes,1 and also
independently increases the risk of CVD and death.4 Careful titration of
insulin is therefore required in people with reduced kidney function, to
minimize the risk of hypoglycaemia.5 Newer basal insulin analogues, such
as insulin degludec 100 units/mL or 200 units/mL (degludec U100 or
U200) and insulin glargine 300 units/mL (glargine U300), have more
stable and prolonged pharmacokinetic/pharmacodynamic profiles than
their first-generation predecessors6,7 resulting in reduced glycaemic
variability and allowing for more flexible dosing and reduced risk of
hypoglycaemia.8,9
A post hoc analysis of the BRIGHT trial showed a greater differ-
ence in reduction of glycated haemoglobin (HbA1c) levels with
glargine U300 versus degludec U100 in participants with poor kidney
function at baseline (estimated glomerular filtration rate [eGFR]
<60 mL/min/1.73 m2) than in subgroups with less impaired kidney
function.10 The CONCLUDE trial (NCT03078478) investigated the
effect of degludec U200 (degludec) and glargine U300 on
hypoglycaemia in adults with basal insulin-treated T2D who had at
least one risk criterion for hypoglycaemia,11 one of which was
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moderate CKD (eGFR 30-59 mL/min/1.73m2). Participants with an
eGFR lower than 30 mL/min/1.73 m2 were excluded. The CON-
CLUDE study design and methods have previously been
reported.11,12 In February 2018, a protocol amendment led to a trial
extension to a total duration of up to 94 weeks with up to 88 weeks
of active treatment, including a maintenance period of 36 weeks.12
The primary endpoint was not met, with the rate of symptomatic
hypoglycaemia not significantly lower with degludec U200 versus
glargine U300.11 Other, exploratory post hoc analyses demonstrated
lower rates of nocturnal symptomatic hypoglycaemic events and
severe hypoglycaemia during the maintenance period and a signifi-
cantly greater, but not clinically meaningful, reduction in mean HbA1c
from baseline to end of treatment (EOT) with degludec versus glargine
U300 (5.9 vs. 5.0 mmol/mol [0.54 vs. 0.46%]).11 The mean
(± standard deviation [SD]) dose of degludec was also lower than that for






















































Overall symptomatic hypoglycaemia 
eGFR subgroup (mL/min/1.73 m2)
30–60 (n = 282)
60–<90 (n = 623)
≥90 (n = 587)
Primary analysis
Nocturnal symptomatic hypoglycaemia 
eGFR subgroup (mL/min/1.73 m2)
30–60 (n = 282)
60–<90 (n = 623)
≥90 (n = 578)
Primary analysis
Severe hypoglycaemia 
eGFR subgroup (mL/min/1.73 m2)
30–60 (n = 282)†
60–<90 (n = 623)†
≥90 (n = 578)†
Primary analysis11
Events/100 participant-years of observation
F IGURE 1 Hypoglycaemia endpoints, by baseline estimated glomerular filtration rate (eGFR) subgroup. Overall symptomatic hypoglycaemic
events were defined as severe (requiring third-party assistance)13 or confirmed blood glucose <3.1 mmol/L [with symptoms]). Nocturnal
symptomatic hypoglycaemic events were defined as severe or blood-glucose confirmed with symptoms, occurring between 00:01 and 05:59 AM.
The number of hypoglycaemic events was analysed using a negative binomial regression model (log link) with the logarithm of the time period in
which a hypoglycaemic event was considered treatment emergent as offset. The model included treatment, number of oral antidiabetic drugs,
region, gender, dosing time and interaction of kidney function group with treatment as fixed factors, and age as a covariate. †Because of a very
low number of events, severe hypoglycaemia was analysed using a simplified model. CI, confidence interval; degludec, insulin degludec; glargine
























eGFR subgroup (mL/min/1.73 m2)
30–60 (n = 261)
60–<90 (n = 579)
≥90 (n = 554)
Primary analysis11,14





–0.10 [–0.18; –0.02 ]
F IGURE 2 Change frombaseline to end of treatment (EOT) in glycated haemoglobin (HbA1c), by baseline estimated glomerular filtration rate (eGFR)
subgroup.Mean change inHbA1c from baseline to EOTwas analysed using amixedmodel for repeatedmeasureswith an unstructured residual
covariancematrix. Treatment, number of oral antidiabetic drugs, region, sex, dosing time, and interaction between treatment and eGFR categorywere
included as fixed factors. Age and baselineHbA1cwere included as covariates. Themodel included the interaction between visit number and all
explanatory variables. CI, confidence interval; degludec, insulin degludec 200 units/mL; glargineU300, insulin glargine 300 units/mL; SD, standard
deviation
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As the risk criteria for hypoglycaemia in CONCLUDE included
moderate CKD,11 the study allowed additional analyses on the impact
of renal function on the safety and efficacy of degludec versus
glargine U300. Therefore, in a post hoc analysis, we assessed mean
change in rates of overall symptomatic, nocturnal symptomatic and
severe hypoglycaemia during the 36-week maintenance period (during
which the data would not be confounded by effective differences in
titration of two insulins with different unit potencies), HbA1c from
baseline to EOT, and EOT total daily insulin dose, stratified by base-
line eGFR (30-60, 60-<90 or ≥ 90 mL/min/1.73 m2).
CONCLUDE randomized 805 participants to degludec and 804 to
glargine U300. The eGFR 30 to 60 mL/min/1.73 m2, 60 to <90
mL/min/1.73 m2 and ≥ 90 mL/min/1.73 m2 subgroups included
174, 325 and 306 participants, respectively, in the degludec treatment
arm, and 149, 345 and 310 participants in the glargine U300 treat-
ment arm. Baseline characteristics were generally similar between
insulin treatment groups within each of the eGFR subgroups
(Table S1). Participants with CKD stage III (eGFR 30-60 mL/
min/1.73 m2) tended to be older than those in the other eGFR sub-
groups, and to have had a longer duration of diabetes.
The rate of overall symptomatic hypoglycaemia increased progres-
sively with declining eGFR in both treatment arms (Figure 1). The
hypoglycaemia rate ratios in the eGFR subgroups were comparable
with the primary analysis for all hypoglycaemia endpoints assessed,
with numerically lower estimated rates of hypoglycaemia observed with
degludec compared with glargine U300. No significant treatment-eGFR
subgroup heterogeneity was observed for degludec and glargine U300
comparisons for any of the hypoglycaemia endpoints measured (overall
symptomatic hypoglycaemia: P interaction = 0.919; nocturnal symp-
tomatic hypoglycaemia: P interaction = 0.299; severe hypoglycaemia: P
interaction = 0.957 [Figure 1]).
When comparing HbA1c change from baseline to EOT between
the degludec and glargine U300 groups, the treatment difference was
similar in the eGFR subgroups (P interaction = 0.842), and comparable
to what was seen in the primary analysis: estimated treatment differ-
ence 1.07 (95% confidence interval [CI] 1.94, 0.20) mmol/mol
(0.10 [95% CI 0.18, 0.02]%),11 with a slightly greater, although
not clinically significant, decrease in HbA1c with degludec versus
glargine U300 (Figure 2). The HbA1c treatment differences for
degludec versus glargine U300 were 0.52 (95% CI 2.53, 1.48)
mmol/mol (0.05 [95% CI 0.23, 0.14]%), 1.18 (95% CI 2.52,
0.17) mmol/mol (0.11 [95% CI 0.23, 0.02]%) and 1.20 (95% CI
2.59, 0.19) mmol/mol (0.11% [95% CI 0.24, 0.02]) in the eGFR
30 to 60 mL/min/1.73 m2, 60 to <90 mL/min/1.73 m2 and ≥ 90 mL/
min/1.73 m2 subgroups, respectively.
The mean EOT total daily insulin dose was lower with degludec
versus glargine U300 in all three eGFR subgroups, consistent with
data reported in the primary analysis (Table S2). The mean (SD) dose
ranged from 60.9 (40.6) U to 73.6 (56.5) U with degludec, and from
65.3 (43.3) U to 78.8 (52.5) U with glargine U300; higher doses of
both insulins were used in patients in the higher eGFR subgroups. The
treatment ratios for mean EOT total daily insulin dose ratios for
degludec versus glargine U300 were 0.95 (95% CI 0.80, 1.12), 0.87
(95% CI 0.77, 0.97) and 0.90 (95% CI 0.80, 1.01) in the eGFR 30 to
60 mL/min/1.73 m2, 60 to <90 mL/min/1.73 m2 and ≥ 90 mL/
min/1.73 m2 subgroups, respectively, while the ratio was 0.88 (95%
CI 0.83, 0.94) in the primary analysis.11,14 No significant interaction
was seen between insulin type and eGFR subgroup in terms of the
EOT daily insulin dose (interaction P = 0.688).
In this post hoc analysis of CONCLUDE trial data, rate ratios for
overall symptomatic hypoglycaemia did not differ significantly
between insulin treatments by eGFR subgroup and were consistent
with the primary analysis. Further, irrespective of renal function, there
was a small but consistent greater reduction in HbA1c from baseline
to EOT, and a lower total daily insulin dose with degludec versus
glargine U300.
Our findings for change in HbA1c (a similar treatment difference
between degludec and glargine U300 across the eGFR subgroups) are in
contrast to those of the recently published post hoc analysis of the
BRIGHT trial, which suggested a greater reduction in HbA1c from base-
line to week 24 in insulin-naïve patients (least squares mean differen-
ce 4.7 [95% CI –8.1, 1.4] mmol/mol [0.43 {95% CI 0.74,
0.12}%]) with glargine U300 versus degludec U100 in the lowest eGFR
subgroup (<60 mL/min/1.73 m2).10 However, that result was based on a
subgroup of only 47 (10.1%) participants in the glargine U300 arm and
49 (10.6%) participants in the degludec arm meeting the <60 mL/
min/1.73 m2 criterion. Our CONCLUDE analysis included more than
three times the number of participants in the low eGFR 30 to 60 mL/
min/1.73 m2 subgroups (174 [21.6%] in the degludec arm and
149 [18.5%] in the glargine U300 arm), hence, in the absence of a dedi-
cated trial comparing the two insulin analogues in moderate kidney insuf-
ficiency, this analysis may provide more accurate estimates. In addition,
of the participants in BRIGHT who were treated with glargine U300, a
greater proportion within the low eGFR <60 mL/min/1.73 m2 subgroup
were on a sulphonylurea medication at baseline (76.6%) than in the other
subgroups (59.9% with eGFR 60 to <90 mL/min/1.73 m2 and 65.4%
with eGFR ≥90 mL/min/1.73 m2). This could have disproportionately
impacted end-of-trial HbA1c. In contrast, patients treated with
sulphonylureas were excluded from CONCLUDE.
Similarly to our analysis, the incidence of hypoglycaemia was
found to increase with decreasing eGFR in the BRIGHT trial, with no
heterogeneity by treatment effect observed across eGFR subgroups
for the incidence of confirmed hypoglycaemia (<3.0 mmol/L
and ≤3.9 mmol/L) over 24 weeks. In addition, similarly to our analysis,
mean insulin doses were higher for glargine U300 (range
0.47-0.61 units/kg) compared with degludec (range 0.35-0.44 units/
kg) at 24 weeks, irrespective of eGFR subgroup, in the BRIGHT trial.
It is possible that some differences in results between the BRIGHT
analysis and the present analysis may be attributable to differences in
the patient populations and trial design. BRIGHT (N = 929) was a smaller
study than CONCLUDE (N = 1609) with a shorter treatment period
(24 weeks, compared with up to 88 weeks in CONCLUDE).11,15 The
BRIGHT trial included insulin-naïve people with T2D who were at lower
risk of hypoglycaemia,15 whereas CONCLUDE included insulin-
experienced individuals with T2D and additional hypoglycaemia risk fac-
tors.11 The mean duration of diabetes within the eGFR subgroups in
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BRIGHT was also generally shorter than in CONCLUDE (range
9.3-15.4 years vs. 12.5-18.6 years, respectively). Moreover, the two trials
had different titration algorithms, with an FBG target of 4.4 to
5.6 mmol/L in BRIGHT and 4.0 to 5.0 mmol/L in CONCLUDE.
Underlying mechanisms for any hypothetical differential effects
of the two insulins based on kidney function are yet to be convinc-
ingly elucidated. Low serum albumin concentration has been associ-
ated with an increased risk of end-stage kidney disease.16
As degludec, and not glargine U300, is albumin-bound,17 it has been
postulated that there could be a greater risk of hypoglycaemia with
degludec in low albumin/eGFR conditions. Results from a small-scale
crossover study suggested that degludec was associated with a higher
risk of hypoglycaemia than glargine U300 in T2D participants with
low albumin concentrations.18 However, these data were limited by
the short study period, lack of adjustment in starting insulin dose and
heterogenous prior therapies in the study population.19 Of note, nei-
ther BRIGHT nor CONCLUDE measured albumin levels. A post hoc
analysis of the DEVOTE trial did not indicate an increased relative risk
of hypoglycaemia for degludec versus glargine U100 in people with
low albumin levels (<3.0 g/dL; n = 12) and did not demonstrate any
albumin-related safety signal concerning degludec.19,20 The hypothe-
sis that degludec may have increased risk of hypoglycaemia in low
albumin states appears improbable given that, at steady state, this
insulin monomer occupies <0.01% of total albumin molecules, and the
fraction occupied would remain negligible even in people with
hypoalbuminaemia.19 Furthermore, degludec, like any insulin, is indi-
vidually titrated to the patient's glycaemic response. Therefore, for
the free degludec fraction to increase significantly in an individual,
there would need to be extreme acute changes in that person's albu-
min concentration.
In summary, this post hoc analysis of CONCLUDE found that rate
ratios for hypoglycaemia were consistent with the primary analyses
across kidney impairment subgroups. Furthermore, irrespective of kid-
ney function, there was a small but consistent greater reduction in
HbA1c from baseline and a lower total daily insulin dose with
degludec versus glargine U300. It can therefore be concluded that
degludec is a well-tolerated and efficacious treatment option for peo-
ple with T2D and kidney impairment.
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